143 results about "Biological condition" patented technology

The invention is directed to compositions and methods for selectively reducing the expression of a gene product from a desired target gene in a cell, as well as for treating diseases caused by the expression of the gene. More particularly, the invention is directed to compositions that contain double stranded RNA (“dsRNA”), and methods for preparing them, that are capable of reducing the expression of target genes in eukaryotic cells. The dsRNA has a first oligonucleotide sequence that is between 25 and about 30 nucleotides in length and a second oligonucleotide sequence that anneals to the first sequence under biological conditions. In addition, a region of one of the sequences of the dsRNA having a sequence length of at least 19 nucleotides is sufficiently complementary to a nucleotide sequence of the RNA produced from the target gene to trigger the destruction of the target RNA by the RNAi machinery.

The invention is directed to compositions and methods for selectively reducing the expression of a gene product from a desired target gene in a cell, as well as for treating diseases caused by the expression of the gene. More particularly, the invention is directed to compositions that contain double stranded RNA (“dsRNA”), and methods for preparing them, that are capable of reducing the expression of target genes in eukaryotic cells. The dsRNA has a first oligonucleotide sequence that is between 25 and about 30 nucleotides in length and a second oligonucleotide sequence that anneals to the first sequence under biological conditions. In addition, a region of one of the sequences of the dsRNA having a sequence length of at least 19 nucleotides is sufficiently complementary to a nucleotide sequence of the RNA produced from the target gene to trigger the destruction of the target RNA by the RNAi machinery.

The present teachings provide methods for diagnosing biological conditions, including cancer. In some embodiments, a test sample is collected from a subject such as a clinical patient, wherein the test sample comprises background tissue and may or may not contain cells from a tissue of interest. Observation of a target miRNA normally present in a tissue of interest, but collected in an anatomical location ectopic to the tissue of interest, can be indicative of a biological condition. The present teachings further provide exponential amplification techniques applicable to performing these analyses.

Systems and methods for localizing the position of a wireless device using a plurality of coordinated highly directional or adaptive antennas to detect signals from the wireless device. Because of the directional nature and / or adaptive processing of the antennas, off-angle multipath signals resulting from reflection and scattering as the wireless signal propagates through a cluttered environment are rejected by the antennas and processing. As a result, the antennas pass primarily direct path signals from the wireless device to the location estimator. The time of arrival of the signal and the angle of arrival at each antenna are used to in the location estimator to calculate the position of the wireless device. Various robust inversion techniques may also be applied to the data to minimize the effect of residual multipath-corrupted detections. Furthermore, the systems and methods include specialized wireless devices that provide locating signals and signals related to the biological condition of their owner.

In an apparatus for measuring a biological condition of a living body, a light emitting unit emits individually first and second lights to a measurement portion of the living body. The first and second lights have first and second wavelengths, respectively. The first and second wavelengths are different from each other. A light receiving unit receives first and second reflection lights to generate first and second detection signals based on the first and second reflection lights, respectively. The first and second reflection lights are based on the first light reflected from the measurement portion and the second light reflected therefrom, respectively. The first and second detection signals have different characteristics from each other due to the difference between the first and second wavelengths. A measuring unit measures the biological condition based on the different characteristics of the first and second detection signals.

A biological condition evaluation apparatus determines a symptom of a heart abnormality based on at least one index calculated from a heartbeat interval and / or a pulse interval. The apparatus determines whether it is in a referential period where an amount of change in the index is comparatively small. The apparatus determines whether a plurality of conditions are satisfied or not in an evaluation period set after the referential period. One condition is that an amount of change in the index in the evaluation period is greater than that observed during the referential period. Another condition is that a rate of change in the index is equal to or greater than a predetermined threshold value. The apparatus determines that there is a symptom of a heart abnormality, when both the conditions are satisfied.

The subject invention provides materials and methods for modulating a variety of biological factors to treat biological conditions associated with the factors. In one embodiment of the invention, a cysteamine compound is administered to a patient to treat hypercholesterolemia and / or complications associated with hypercholesterolemia. In another embodiment, a cysteamine compound is administered to a patient to prevent the onset of diabetes in an at-risk patient and / or treat or prevent the onset of diabetes-associated complications.

Mobile consumer devices are used to communicate with consumer medical devices to either provide update data to the consumer medical device or to obtain data from the consumer medical device. Some data is used to evaluate performance and operation of the medical device or a biological condition of the living being that is being treated with the medical device. Other data is used to calibrate and update the consumer medical device or to enable or disable certain functionality of the medical device. Communications between the medical devices and mobile consumer devices can be performed automatically or on demand, as initiated by a user, a third party, or in response to predetermined conditions detected by the devices.

The present invention provides kits, apparatus and methods for determining a biological condition in a mammalian subject, the method includes incubating a specimen from a patient with at least one composition in a kit for a predetermined period of time to form at least one reaction product, when the subject has said biological condition, and receiving an indication of the at least one reaction product responsive to at least one reporter element in the kit thereby providing the indication of the biological condition in the subject.

The present provides a carrier molecule for transporting a polyanioic macromolecule such as a nucleic acid across a biological barrier of a cell. The carrier has a biocompatible backbone polymer with two or more polycationic polymer fragments covalently linked. In one embodiment, the backbone polymer is polyethylene glycol (PEG) and the polycationic polymer is polyethylenimine (PEI). The copolymer carrier molecule can be complexed with a polyanionic macromolecule such as a nucleic acid (NA). The NA / copolymer complex is stable in biological conditions by forming a special coreshell-like micelle structure. The nucleic acid can be rapidly released from the complex when biodegradation linker are used to bind the polycationic polymer fragments to the polymer backbone. The carriers and complexes of the invention can be used tin methods of delivering the polycainonic macromolecules to cells both in vitro and in vivo.

A sound management system for use by a user located within an environment includes a memory device for storing a selection of sounds. The sounds can be music and / or various “colors” of noise (e.g., white, pink, and brown). A controller is used to select one particular stored sound based on a measured biological condition of the user, such as stress or fatigue, or an environmental condition of the environment, such as ambient noise. According to one embodiment, the system is used in conjunction with a sit / stand desk and the sound selection is made in response to changes in the desk height. The selected sound is selected to help abate or mitigate distracting sounds in the environment, such as people talking. The selected sounds are played to the user through headphones worn by the user, or through nearby speakers.

A system for monitoring strain as an indicator of biological conditions, such as spinal fusion, glucose levels, spinal loading, and heart rate. The system includes an inter-digitated capacitor sensor, and RF transmitter, and an associated antenna, all of which are microminiature or microscopic in size and can be implanted in a biological host such as a human or animal. An inductively coupled power supply is also employed to avoid the need for implantation of chemical batteries. Power is provided to the sensor and transmitter, and data is transmitted from the sensor, when an external receiving device, such as a handheld RF ID type receiver, is placed proximate the location of the implanted sensor, transmitter and inductively coupled power supply. The implanted sensor, transmitter and inductively coupled power supply can be left in place permanently or removed when desired.

Intravaginal drug delivery devices, including intravaginal rings, are provided herein. The devices comprise a polyether urethane composition and a pharmaceutically effective amount of at least one vaginally administrable drug homogeneously distributed throughout the polyether urethane. The devices are capable of exhibiting a substantially zero order release profile of drug over extended periods of time. Also disclosed are methods for making the devices and methods of using the devices to prevent or treat a biological condition.

Compounds of formula IA or IB are provided where X1, X2 and X3 are independently selected from H or hydroxy protecting groups and R1 is selected from straight or branched chain alkyl groups having from 1 to 8 carbon atoms; straight or branched chain alkenyl groups having from 2 to 8 carbon atoms; straight or branched chain hydroxy-substituted alkyl groups having from 1 to 8 carbon atoms; straight and branched chain hydroxy-substituted alkenyl groups having from 2 to 8 carbon atoms. Such compounds are used in preparing pharmaceutical compositions and are useful in treating a variety of biological conditions.

The invention is directed to compositions and methods for selectively reducing the expression of a gene product from a desired target gene in a cell, as well as for treating diseases caused by the expression of the gene. More particularly, the invention is directed to compositions that contain double stranded RNA (“dsRNA”), and methods for preparing them, that are capable of reducing the expression of target genes in eukaryotic cells. The dsRNA has a first oligonucleotide sequence that is between 25 and about 30 nucleotides in length and a second oligonucleotide sequence that anneals to the first sequence under biological conditions. In addition, a region of one of the sequences of the dsRNA having a sequence length of at least 19 nucleotides is sufficiently complementary to a nucleotide sequence of the RNA produced from the target gene to trigger the destruction of the target RNA by the RNAi machinery.

Compounds of formula IA or IB are provided where X1, X2 and X3 are independently selected from H or hydroxy protecting groups and R1 is selected from straight or branched chain alkyl groups having from 1 to 8 carbon atoms; straight or branched chain alkenyl groups having from 2 to 8 carbon atoms; straight or branched chain hydroxy-substituted alkyl groups having from 1 to 8 carbon atoms; straight and branched chain hydroxy-substituted alkenyl groups having from 2 to 8 carbon atoms. Such compounds are used in preparing pharmaceutical compositions and are useful in treating a variety of biological conditions.

The invention is directed to compositions and methods for selectively reducing the expression of a gene product from a desired target gene in a cell, as well as for treating diseases caused by the expression of the gene. More particularly, the invention is directed to compositions that contain double stranded RNA (“dsRNA”), and methods for preparing them, that are capable of reducing the expression of target genes in eukaryotic cells. The dsRNA has a first oligonucleotide sequence that is between 25 and about 30 nucleotides in length and a second oligonucleotide sequence that anneals to the first sequence under biological conditions. In addition, a region of one of the sequences of the dsRNA having a sequence length of at least 19 nucleotides is sufficiently complementary to a nucleotide sequence of the RNA produced from the target gene to trigger the destruction of the target RNA by the RNAi machinery.

There is provided a medical image processing apparatus including an image-extracting section extracting a frame image from in vivo motion picture data picked up by an in vivo image pickup device or a plurality of consecutively picked-up still image data, and an image analysis section analyzing the frame image extracted by the image-extracting section to output an image analysis result. The image analysis section includes a first biological-feature detection section detecting a first biological feature, a second biological-feature detection section detecting, based on a detection result obtained by the first biological feature detection section, a second biological feature in a frame image picked up temporally before or after the image used for detection by the first biological feature detection section; and a condition determination section making a determination for a biological condition based on a detection result obtained by the second biological feature detection section to output the determination.

Individualized responsive dosing dietary supplement systems, compositions, methods of dosing, and processes of producing the same, which allow a consumer to generate individualistic biological responses / effects. More specifically, a dietary supplement system for generating individualized biological conditions / responses which utilizes ultra-low dosage amounts of vitamins, minerals, amino acids, co-enzymes, and / or other nutrients in a bio-active delivery system which preferably avoids first pass metabolism, such that an individual may take multiple doses of the same or different dietary supplement based on varying desired biological response within each 24 period is also disclosed.

The invention discloses a three-dimensional flexible neural microelectrode and a manufacturing method thereof. The microelectrode uses a flexible polymer as a base material, and performs progressive electroplating through a circular pattern design of a metal seed layer to form smooth three-dimensional convex features. The electrode site structure can not only ensure good contact between the electrode site and the nerve cells, but also avoid damage to the nerve tissue caused by the sharp edges and corners of the raised electrode sites in the existing three-dimensional neural microelectrode. In addition, through the composite electroplating process in the electroplating process, that is, nano-scale dispersants are added to the electroplating solution to form a submicron-scale microporous structure on the surface of the electrode, increasing the surface area of ​​the electrode site, thereby enhancing the current output capability of the electrode and ensuring the nerve. Effective stimulation of microelectrodes under the constraints of biosafety conditions. The three-dimensional flexible neural microelectrode provided by the invention can be widely used in the fields of neurological disease treatment, neurological rehabilitation, neurobiological basic research and the like.

Administration of low molecular weight (10,000-20,000 Daltons, or lower) pectins, particularly modified citrus pectins (MCP), like PectaSol-C reduces galectins-3 levels in vivo. Reduction of galectin-3 levels by MCP inhibits inflammation, inhibits fibrosis formation in organs and tissues, and inhibits cancer formation, progression, transformation and metastases. The reduction in circulating, serum and cellular galectin-3, inherently resulting from the administration of MCP, provides benefit over a spectrum of biological conditions, as evidenced by in vivo trials.

A vaginal therapeutic device made of copper metal has a shape to fit in the vagina and utilizes the copper metal as an antimicrobial agent to therapeutically treat abnormal biological conditions in the vagina.

Individualized responsive dosing pharmanutrient systems, compositions, methods of dosing, and processes of producing the same, which allow a consumer to generate individualistic biological responses / effects. More specifically, a pharmanutrient system for generating individualized biological conditions / responses which utilizes ultra-low dosage amounts of vitamins, minerals, amino acids, co-enzymes, organics substrates, inorganic or synthetic substrates, biological components, and / or other nutrients incorporated or provided with a pharmacologically active ingredient in a bio-active delivery system which preferably avoids first pass metabolism, such that an individual may take multiple doses of the same or different pharmanutrient based on varying desired biological response within each dosing period.

A system provided in accordance with the present invention comprises a sever unit (100), which serves as an apparatus for processing information concerning a biological condition information, and a client unit (200), which serves as an information terminal of a provider of the information on the biological condition communicably connected to the server unit (100) via a network (300). The server unit (100) determines a composite index reflecting a plurality of metabolites indicative of the biological condition based on the information on the biological condition acquired from the client unit (200).

There is a need for providing a vehicular music replay system that can allow a car user to select a music source appropriate to the user's character or biological condition even from genres unknown to the user, allow even a first music source to be felt suited for the user, and consequently enhance an emotion about encounter with an unknown music source. The system stores music sources to be replayed in music source databases in association with applicable user state data reflecting a user state containing at least one of a user character, mental condition, and physical condition. The system retrieves a music source corresponding to the current user state acquired in a car. During the retrieval, a higher retrieval priority is provided for a music source having a lower replay history in the past.